NASDAQ:WGS

GeneDx (WGS) Stock Price, News & Analysis

GeneDx logo
$51.98 +0.03 (+0.05%)
As of 11:30 AM Eastern
This is a fair market value price provided by Massive. Learn more.

About GeneDx Stock (NASDAQ:WGS)

Advanced

Key Stats

Today's Range
$51.37
▼
$54.80
50-Day Range
$47.29
▼
$104.95
52-Week Range
$32.21
▼
$170.87
Volume
232,239 shs
Average Volume
945,660 shs
Market Capitalization
$1.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$90.14
Consensus Rating
Moderate Buy

Company Overview

GeneDx is a genomic testing company focused on helping clinicians diagnose rare and inherited conditions. Its services include whole exome and whole genome sequencing, along with other genetic tests and clinical interpretation of results.

The company’s testing is used by healthcare providers to support diagnosis and care decisions, particularly for patients with suspected rare genetic disorders. GeneDx also offers testing related to hereditary cancer risk.

Founded in 2000 by researchers with experience at the National Institutes of Health, GeneDx has developed its business around applying genomic information in clinical care. The company is based in the United States and serves healthcare providers and patients through its diagnostic services.

AI Generated. May Contain Errors.

GeneDx Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
66th Percentile Overall Score

WGS MarketRank™: 
3.297175603765 of 5 stars

GeneDx scored higher than 66% of companies evaluated by MarketBeat, and ranked 545th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    GeneDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 1 strong buy rating, 7 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    GeneDx has a consensus price target of $90.14, representing about 73.7% upside from its current price of $51.91.

  • Amount of Analyst Coverage

    GeneDx has only been the subject of 4 research reports in the past 90 days.

  • Read more about GeneDx's stock forecast and price target.
  • Earnings Growth

    Earnings for GeneDx are expected to grow in the coming year, from ($0.37) to $1.26 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of GeneDx is -13.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of GeneDx is -13.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    GeneDx has a P/B Ratio of 6.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    29.36% of the float of GeneDx has been sold short.
  • Short Interest Ratio / Days to Cover

    GeneDx has a short interest ratio ("days to cover") of 7.27.
  • Change versus previous month

    Short interest in GeneDx has recently increased by 8.83%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    GeneDx does not currently pay a dividend.

  • Dividend Growth

    GeneDx does not have a long track record of dividend growth.

  • News Sentiment

    GeneDx has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for GeneDx this week, compared to 8 articles on an average week.
  • Search Interest

    8 people have searched for WGS on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added GeneDx to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, GeneDx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,808,056.00 in company stock.

  • Percentage Held by Insiders

    25.17% of the stock of GeneDx is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    61.72% of the stock of GeneDx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about GeneDx's insider trading history.
Receive WGS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GeneDx and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

WGS Stock News Headlines

GeneDx Holdings Corp. Announces Management Changes
Your $7 scanner is waiting
The Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which stock, what price, and when to exit. The list reads the same whether you've traded for twenty years or twenty days, and it doesn't depend on account size. If it's not for you, refund the $7 and still keep the scanner for the full year. One payment, no re-bills.tc pixel
GeneDx Announces Leadership Transition
GeneDx Earnings Call Highlights Growth and Profitability
GeneDx to Participate in Upcoming Investor Conferences
See More Headlines

WGS Stock Analysis - Frequently Asked Questions

GeneDx's stock was trading at $130.06 at the start of the year. Since then, WGS shares have decreased by 60.1% and is now trading at $51.9080.

GeneDx Holdings Corp. (NASDAQ:WGS) issued its earnings results on Monday, November, 9th. The company reported $0.28 earnings per share for the quarter, topping analysts' consensus estimates of $0.07 by $0.21. The firm earned $123.10 million during the quarter, compared to the consensus estimate of $122.93 million. GeneDx had a positive trailing twelve-month return on equity of 1.98% and a negative net margin of 24.10%.
Read the conference call transcript
.

Shares of GeneDx reverse split on the morning of Thursday, May 4th 2023.The 1-33 reverse split was announced on Thursday, May 4th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

GeneDx's top institutional investors include William Blair Investment Management LLC (5.23%), Sumitomo Mitsui Trust Group Inc. (2.22%), Assenagon Asset Management S.A. (2.12%) and State Street Corp (1.78%). Insiders that own company stock include Keith A Meister, Casdin Capital, Llc, School Of Medicine At Mo Icahn, Opko Health, Inc, Katherine Stueland, Kevin Feeley, Kareem Saad, Joshua Ruch, Jason Ryan and Bryan Dechairo.
View institutional ownership trends
.

Shares of WGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that GeneDx investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), CrowdStrike (CRWD), Tesla (TSLA), Alibaba Group (BABA), Advanced Micro Devices (AMD) and Taiwan Semiconductor Manufacturing (TSM).

Company Calendar

Last Earnings
11/09/2026
Today
11/19/2026
38th Annual Healthcare Conference
12/02/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Providers & Services
Sub-Industry
Healthcare Services
Current Symbol
NASDAQ:WGS
CIK
1818331
Fax
N/A
Employees
1,300
Year Founded
2000

Price Target and Rating

High Price Target
$150.00
Low Price Target
$63.00
Potential Upside/Downside
+73.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.78)
Trailing P/E Ratio
N/A
Forward P/E Ratio
41.20
P/E Growth
N/A
Net Income
-$21.02 million
Net Margins
-24.10%
Pretax Margin
-24.14%
Return on Equity
1.98%
Return on Assets
1.02%

Debt

Debt-to-Equity Ratio
0.60
Current Ratio
4.16
Quick Ratio
3.85

Sales & Book Value

Annual Sales
$460.78 million
Price / Sales
3.38
Cash Flow
$2.52 per share
Price / Cash Flow
20.63
Book Value
$8.16 per share
Price / Book
6.36

Miscellaneous

Outstanding Shares
29,972,000
Free Float
22,428,000
Market Cap
$1.56 billion
Optionable
Optionable
Beta
2.00

Social Links

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

This page (NASDAQ:WGS) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners